Loading stock data…
GRFS
$7.34+0.01 (+0.14%)
After Hours$7.34+0.00 (+0.00%)· Last close Jun 9
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grifols, S.A. in the Healthcare sector is trading at $7.34. Wall Street consensus targets $10.87 (2 analysts), implying a +48.0% move over the next 12 months. The stock is currently near its 52-week low of $7.32, remaining 17.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +48.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.34
Potential Downside
0%
Whystock Fair Value$7.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.32%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.38%
Volume
Today's trading volume
733,810
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late M
Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Grifols, S.A. (NASDAQ:GRFS) is among the most undervalued stocks. TheFly reported on May 12 that Deutsche Bank reduced its price target on GRFS from €11 to €10 while reaffirming a Hold rating on the stock. Earlier on May 7, Grifols, […]
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
European equities traded in the US as American depositary receipts were trending slightly lower late
How The Grifols (BME:GRF) Investment Story Is Shifting With New Analyst Caution
Analysts have trimmed their fair value price target for Grifols from €15.08 to €14.65, while broader published price targets now cluster in the €10 to €11 range. This reset lines up with a more cautious tone in recent research, where questions around revenue visibility and slower albumin and alpha-1 volumes have led to reduced conviction on upside. As you read on, you will see how this evolving narrative might shape the way you track the stock from here. Analyst Price Targets don't always...